A Trial of a Single-tablet Regimen of Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Disoproxil Fumarate for the Initial Treatment of Human Immunodeficiency Virus Type 2 Infection in a Resource-limited Setting: 48-Week Results From Senegal, West Africa

We report the first trial of elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate, an INI-based, single-tablet regimen, in human immunodeficiency virus -2– infected, ARV-naive adults living in Senegal, West Africa

Selly Ba; Dana N Raugi; Robert A Smith; Fatima Sall; Khadim Faye; Stephen E Hawes; Papa Salif Sow; Moussa Seydi; Geoffrey S Gottlieb; Fatou Traore; Marie Pierre Sy; Bintou Diaw; Mbaye Ndoye; Amadou Bale Diop; Marianne Fadam Diome; Alassane Niang; Jean Jacques Malomar; ElHadji Ibrahima Sall; Ousseynou Cisse; Ibrahima Tito Tamba; Jean Philippe Diatta; Jacques Sambou; Raphael Bakhoum; Juliette Gomis; Noelle Benzekri; John Lin; Nancy Kiviat; Sally Leong; Sara Masoum; Vincent Wu; Carol Gallardo; Eleanor Espinosa; Ming Chang; Bob Coombs; University of Washington–Dakar HIV-2 Study Group

2018

Scholarcy highlights

  • There is an urgent need for safe and effective antiretroviral therapy for human immunodeficiency virus type 2 infection
  • Our findings support the use of integrase inhibitor–based regimens for HIV-2 treatment
  • We report the first trial of elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate, an INI-based, single-tablet regimen, in HIV-2– infected, ARV-naive adults living in Senegal, West Africa
  • HIV-2 plasma viral loads was detectable in 73%
  • There was no significant difference in CD4 count increase between individuals with vs without detectable HIV-2 pVL prior to initiation of E/C/F/TDF, suggesting that there may be some immunological benefit in treating HIV-2–infected individuals with undetectable viral loads at baseline
  • Several retrospective cohort studies with non-INI-based regimens have reported less robust CD4 cell count reconstitution in HIV-2–infected patients on ART compared with human immunodeficiency virus type 1, these comparisons may have been confounded by differences in patient characteristics and ART regimens
  • Our data suggest that there is a potential benefit in treating human immunodeficiency virus-2–infected individuals with either low or undetectable viral loads, as well as those with CD4 counts >500 cells/μL

Need more features? Save interactive summary cards to your Scholarcy Library.